세계의 온바디 인젝터 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for On-body Injectors was estimated to be worth US$ 178 million in 2024 and is forecast to a readjusted size of US$ 518 million by 2031 with a CAGR of 16.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on On-body Injectors cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

On-body injectors, also known as on-body delivery systems (OBDS), are medical devices designed to deliver a controlled dose of medication or therapeutic substances subcutaneously (under the skin) over a specified period. These devices are typically worn on the body and are used to administer various treatments, including medications, hormones, and biologics. On-body injectors offer several advantages, including increased patient convenience, improved medication adherence, and the ability to deliver complex therapies. The scope of this report is non-insulin On-body injectors.

In 2024, the global sales ofnon-insulin on-body injectorsreached approximately5 million units, with an average market price of$35 per unit.

North America is currently the largest market for on-body injectors, driven by high healthcare spending, early adoption of advanced drug delivery technologies, and a strong presence of key players such as Amgen (with its Neulasta(R) Onpro(R) kit). The United States leads in the development and approval of wearable drug delivery systems, especially for chronic conditions like cancer and autoimmune diseases. Growing demand for home-based treatment and reduced hospital visits post-COVID-19 has further accelerated market expansion.

Europe is a strong and steadily growing market for on-body injectors, supported by rising prevalence of chronic diseases, aging populations, and robust healthcare infrastructure. Countries such as Germany, the UK, and France are key adopters, with regulatory support for patient-centric drug delivery systems. The focus on reducing hospital burden and improving patient compliance is encouraging healthcare providers to adopt wearable injectors, particularly for biologics and long-term therapies.

Asia-Pacific is the fastest-growing region for on-body injectors, driven by increasing healthcare awareness, expanding middle-class populations, and rising chronic disease incidence. Countries like China, Japan, and South Korea are investing heavily in digital health and self-administered therapies.

This report aims to provide a comprehensive presentation of the global market for On-body Injectors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of On-body Injectors by region & country, by Type, and by Application.

The On-body Injectors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding On-body Injectors.

Market Segmentation

By Company

• West Pharmaceutical Services
• Insulet
• Gerresheimer
• United Therapeutics
• CC Bio
• BD
• Ypsomed
• Enable Injections
• Nemera
• Stevanato Group
• Sonceboz
• Lohmann Therapie-Systeme
• Elcam Drug Delivery Devices (E3D)
• MicroMED
• Altek Medical

Segment by Type

• Electronic Injectors
• Mechanical Injectors

Segment by Application

• Immuno-oncology
• Cardiovascular Diseases
• Neurological Diseases
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of On-body Injectors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of On-body Injectors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of On-body Injectors in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 On-body Injectors Product Introduction
• 1.2 Global On-body Injectors Market Size Forecast
  • 1.2.1 Global On-body Injectors Sales Value (2020-2031)
  • 1.2.2 Global On-body Injectors Sales Volume (2020-2031)
  • 1.2.3 Global On-body Injectors Sales Price (2020-2031)
• 1.3 On-body Injectors Market Trends & Drivers
  • 1.3.1 On-body Injectors Industry Trends
  • 1.3.2 On-body Injectors Market Drivers & Opportunity
  • 1.3.3 On-body Injectors Market Challenges
  • 1.3.4 On-body Injectors Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global On-body Injectors Players Revenue Ranking (2024)
• 2.2 Global On-body Injectors Revenue by Company (2020-2025)
• 2.3 Global On-body Injectors Players Sales Volume Ranking (2024)
• 2.4 Global On-body Injectors Sales Volume by Company Players (2020-2025)
• 2.5 Global On-body Injectors Average Price by Company (2020-2025)
• 2.6 Key Manufacturers On-body Injectors Manufacturing Base and Headquarters
• 2.7 Key Manufacturers On-body Injectors Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of On-body Injectors
• 2.9 On-body Injectors Market Competitive Analysis
  • 2.9.1 On-body Injectors Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by On-body Injectors Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in On-body Injectors as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Electronic Injectors
  • 3.1.2 Mechanical Injectors
• 3.2 Global On-body Injectors Sales Value by Type
  • 3.2.1 Global On-body Injectors Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global On-body Injectors Sales Value, by Type (2020-2031)
  • 3.2.3 Global On-body Injectors Sales Value, by Type (%) (2020-2031)
• 3.3 Global On-body Injectors Sales Volume by Type
  • 3.3.1 Global On-body Injectors Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global On-body Injectors Sales Volume, by Type (2020-2031)
  • 3.3.3 Global On-body Injectors Sales Volume, by Type (%) (2020-2031)
• 3.4 Global On-body Injectors Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Immuno-oncology
  • 4.1.2 Cardiovascular Diseases
  • 4.1.3 Neurological Diseases
  • 4.1.4 Others
• 4.2 Global On-body Injectors Sales Value by Application
  • 4.2.1 Global On-body Injectors Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global On-body Injectors Sales Value, by Application (2020-2031)
  • 4.2.3 Global On-body Injectors Sales Value, by Application (%) (2020-2031)
• 4.3 Global On-body Injectors Sales Volume by Application
  • 4.3.1 Global On-body Injectors Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global On-body Injectors Sales Volume, by Application (2020-2031)
  • 4.3.3 Global On-body Injectors Sales Volume, by Application (%) (2020-2031)
• 4.4 Global On-body Injectors Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global On-body Injectors Sales Value by Region
  • 5.1.1 Global On-body Injectors Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global On-body Injectors Sales Value by Region (2020-2025)
  • 5.1.3 Global On-body Injectors Sales Value by Region (2026-2031)
  • 5.1.4 Global On-body Injectors Sales Value by Region (%), (2020-2031)
• 5.2 Global On-body Injectors Sales Volume by Region
  • 5.2.1 Global On-body Injectors Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global On-body Injectors Sales Volume by Region (2020-2025)
  • 5.2.3 Global On-body Injectors Sales Volume by Region (2026-2031)
  • 5.2.4 Global On-body Injectors Sales Volume by Region (%), (2020-2031)
• 5.3 Global On-body Injectors Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America On-body Injectors Sales Value, 2020-2031
  • 5.4.2 North America On-body Injectors Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe On-body Injectors Sales Value, 2020-2031
  • 5.5.2 Europe On-body Injectors Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific On-body Injectors Sales Value, 2020-2031
  • 5.6.2 Asia Pacific On-body Injectors Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America On-body Injectors Sales Value, 2020-2031
  • 5.7.2 South America On-body Injectors Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa On-body Injectors Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa On-body Injectors Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions On-body Injectors Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions On-body Injectors Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions On-body Injectors Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions On-body Injectors Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States On-body Injectors Sales Value, 2020-2031
  • 6.3.2 United States On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States On-body Injectors Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe On-body Injectors Sales Value, 2020-2031
  • 6.4.2 Europe On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe On-body Injectors Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China On-body Injectors Sales Value, 2020-2031
  • 6.5.2 China On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China On-body Injectors Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan On-body Injectors Sales Value, 2020-2031
  • 6.6.2 Japan On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan On-body Injectors Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea On-body Injectors Sales Value, 2020-2031
  • 6.7.2 South Korea On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea On-body Injectors Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia On-body Injectors Sales Value, 2020-2031
  • 6.8.2 Southeast Asia On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia On-body Injectors Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India On-body Injectors Sales Value, 2020-2031
  • 6.9.2 India On-body Injectors Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India On-body Injectors Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 West Pharmaceutical Services
  • 7.1.1 West Pharmaceutical Services Company Information
  • 7.1.2 West Pharmaceutical Services Introduction and Business Overview
  • 7.1.3 West Pharmaceutical Services On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 West Pharmaceutical Services On-body Injectors Product Offerings
  • 7.1.5 West Pharmaceutical Services Recent Development
• 7.2 Insulet
  • 7.2.1 Insulet Company Information
  • 7.2.2 Insulet Introduction and Business Overview
  • 7.2.3 Insulet On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Insulet On-body Injectors Product Offerings
  • 7.2.5 Insulet Recent Development
• 7.3 Gerresheimer
  • 7.3.1 Gerresheimer Company Information
  • 7.3.2 Gerresheimer Introduction and Business Overview
  • 7.3.3 Gerresheimer On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Gerresheimer On-body Injectors Product Offerings
  • 7.3.5 Gerresheimer Recent Development
• 7.4 United Therapeutics
  • 7.4.1 United Therapeutics Company Information
  • 7.4.2 United Therapeutics Introduction and Business Overview
  • 7.4.3 United Therapeutics On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 United Therapeutics On-body Injectors Product Offerings
  • 7.4.5 United Therapeutics Recent Development
• 7.5 CC Bio
  • 7.5.1 CC Bio Company Information
  • 7.5.2 CC Bio Introduction and Business Overview
  • 7.5.3 CC Bio On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 CC Bio On-body Injectors Product Offerings
  • 7.5.5 CC Bio Recent Development
• 7.6 BD
  • 7.6.1 BD Company Information
  • 7.6.2 BD Introduction and Business Overview
  • 7.6.3 BD On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 BD On-body Injectors Product Offerings
  • 7.6.5 BD Recent Development
• 7.7 Ypsomed
  • 7.7.1 Ypsomed Company Information
  • 7.7.2 Ypsomed Introduction and Business Overview
  • 7.7.3 Ypsomed On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Ypsomed On-body Injectors Product Offerings
  • 7.7.5 Ypsomed Recent Development
• 7.8 Enable Injections
  • 7.8.1 Enable Injections Company Information
  • 7.8.2 Enable Injections Introduction and Business Overview
  • 7.8.3 Enable Injections On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Enable Injections On-body Injectors Product Offerings
  • 7.8.5 Enable Injections Recent Development
• 7.9 Nemera
  • 7.9.1 Nemera Company Information
  • 7.9.2 Nemera Introduction and Business Overview
  • 7.9.3 Nemera On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Nemera On-body Injectors Product Offerings
  • 7.9.5 Nemera Recent Development
• 7.10 Stevanato Group
  • 7.10.1 Stevanato Group Company Information
  • 7.10.2 Stevanato Group Introduction and Business Overview
  • 7.10.3 Stevanato Group On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Stevanato Group On-body Injectors Product Offerings
  • 7.10.5 Stevanato Group Recent Development
• 7.11 Sonceboz
  • 7.11.1 Sonceboz Company Information
  • 7.11.2 Sonceboz Introduction and Business Overview
  • 7.11.3 Sonceboz On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Sonceboz On-body Injectors Product Offerings
  • 7.11.5 Sonceboz Recent Development
• 7.12 Lohmann Therapie-Systeme
  • 7.12.1 Lohmann Therapie-Systeme Company Information
  • 7.12.2 Lohmann Therapie-Systeme Introduction and Business Overview
  • 7.12.3 Lohmann Therapie-Systeme On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 Lohmann Therapie-Systeme On-body Injectors Product Offerings
  • 7.12.5 Lohmann Therapie-Systeme Recent Development
• 7.13 Elcam Drug Delivery Devices (E3D)
  • 7.13.1 Elcam Drug Delivery Devices (E3D) Company Information
  • 7.13.2 Elcam Drug Delivery Devices (E3D) Introduction and Business Overview
  • 7.13.3 Elcam Drug Delivery Devices (E3D) On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 Elcam Drug Delivery Devices (E3D) On-body Injectors Product Offerings
  • 7.13.5 Elcam Drug Delivery Devices (E3D) Recent Development
• 7.14 MicroMED
  • 7.14.1 MicroMED Company Information
  • 7.14.2 MicroMED Introduction and Business Overview
  • 7.14.3 MicroMED On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.14.4 MicroMED On-body Injectors Product Offerings
  • 7.14.5 MicroMED Recent Development
• 7.15 Altek Medical
  • 7.15.1 Altek Medical Company Information
  • 7.15.2 Altek Medical Introduction and Business Overview
  • 7.15.3 Altek Medical On-body Injectors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.15.4 Altek Medical On-body Injectors Product Offerings
  • 7.15.5 Altek Medical Recent Development

8 Industry Chain Analysis

• 8.1 On-body Injectors Industrial Chain
• 8.2 On-body Injectors Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 On-body Injectors Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 On-body Injectors Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer